Displaying 1 - 255 of 255 tests
ABL1 Kinase Domain Mutation Analysis

RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. Analysis includes detection of the common T315I mutation.

Molecular
ALK for Lymphoma

Probes: ALK (2p23)
Disease(s): Anaplastic large cell lymphoma, NHL

FISH
ALK-1 (for heme cases)The ALK1 (ALK1 cline) antibody labels normal human ALK protein and the NPM-ALK chimeric protein, and is a useful tool for the identification of the subgroup of anaplastic large-cell lymphomas (ALCL) that are ALK positive. Immunohistochemistry (IHC)
ALL Adult FISH Panel

Probes: TCF3/PBX1 (E2A/PBX1) t(1;19) | Trisomy or Tetrasomy 4, 6, 10, 17 (Cen 4, Cen 6, Cen 10, Cen 17) | MYC (8q24) | BCR/ABL1/ASS1 t(9;22) | MLL (11q23) | IgH (14q32) |
Disease(s): Acute lymphoblastic (lymphocytic) leukemia (B-cell ALL), B lymphoblastic lymphoma (LBL), adult
Probes may be ordered separately except Centromeres 4 and 17 are paired, and Centromeres 6 and 10 are paired.
Note: STAT processing is available by request for BCR-ABL1. Note STAT along with MD contact name and phone number to receive STAT results.
Note: CDKN2A (p16) Deletion FISH is also available and may be ordered separately. See details here.

FISH
ALL Pediatric FISH Panel

Probes: TCF3/PBX1 (E2A/PBX1) t(1;19) | Trisomy or Tetrasomy 4, 6, 10, 17 (Cen 4, Cen 6, Cen 10, Cen 17) | MYC (8q24) | BCR/ABL1/ASS1 t(9;22) | MLL (11q23) | ETV6/RUNX1 (TEL/AML1) t(12;21) | IgH (14q32)
Disease(s): Acute lymphoblastic (lymphocytic) leukemia (B-cell ALL), B lymphoblastic lymphoma (LBL), pediatric
Probes may be ordered separately except Centromeres 4 and 17 are paired, and Centromeres 6 and 10 are paired.
Note: STAT processing is available by request for BCR-ABL1. Note STAT along with MD contact name and phone number to receive STAT results.
Note: CDKN2A (p16) Deletion FISH is also available and may be ordered separately. See details here.

FISH
AML Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34, CD45, CD117, cMPO, and nTdT (10 markers).

Flow Cytometry
AML Favorable-Risk PanelProbes: RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Disease(s): Acute myeloid leukemia
Probes may be ordered separately.
FISH
AML FISH Panel (New York)

Probes: 5q-, -5 (5p15.2, 5q33-34) | 7q-, -7 (7q31, Cen 7) | Trisomy 8 (Cen 8) | MLL (11q23) | RUNX1T1/RUNX1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Probes may be ordered separately.
Disease(s): AML
Note: STAT processing is available by request for PML-RARA. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
AML Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are cCD3, CD11b, CD13, CD14, CD16, CD19, cCD22, CD33, CD34, CD45, CD64, cCD79a, CD117, CD123, HLA-DR, cMPO, and nTdT (17 markers).

Flow Cytometry
AML Non-Favorable Risk FISH Panel

Probes: RPN1, MECOM (3q21, 3q26.2) | 5q-, -5 (5p15, 5q31, 5q33 | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | DEK/NUP214 (CAN) t(6;9) | MLL (11q23) | ETV6 (12p13) | 17p- (TP53 17p13.1, NF1 17q11.2) | Probes may be ordered separately.
Disease(s):Acute myeloid leukemia

FISH
AML Reflex PanelRoutine cytogenetics with automatic addition of the NeoTYPE™ AML Prognostic Profile when cytogenetics results show intermediate risk including normal cytogenetics, +6, +8, -Y, or del(12p). Molecular
AML Standard FISH Panel

Probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | PML/RARA t(15;17) | CBFB inv(16), t(16;16)
Probes may be ordered separately except +8 and 20q- which are combined.
Disease(s): Acute myeloid leukemia Probes may be ordered separately except +8 and 20q- which are combined.
Note: STAT processing is available by request for PML-RARA. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
Amyloid AThis antibody reacts with amyloid deposits in all formalin-fixed, paraffin embedded (FFPE) tissues, including kidney and rectum. Immunohistochemistry (IHC)
Amyloid PAmyloid P component reacts with all types of amyloid deposits, however, it is also present in normal elastic tissue and basement membranes. The application of Congo red, amyloid P and amyloid A in tissues with amyloid deposits has been shown to be superior to Congo red and other histochemical stains. Immunohistochemistry (IHC)
Annexin A1Annexin A1 (ANXA1), a gene related to phagocytosis, is found to be one of the most highly upregulated genes in hairy cell leukemia. Annexin A1 is strongly expressed on the cell membrane of 97% of hairy cell leukemia cases. Although Annexin A1 is negative in normal B-cells or B-cell tumors other than "classic" hairy cell leukemia, it stains myeloid cells, macrophages, and subsets of benign T-cells. Immunohistochemistry (IHC)
API2/MALT1 t(11;18)Probes: API2/MALT1 t(11;18)
Disease(s): MALT lymphoma, NHL
FISH
ASXL1 Mutation Analysis

Bi-directional sequencing of the majority of exons 13 and 14 of ASXL1, corresponding to amino acids 406-1396.

Molecular
B-ALL Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79a, CD10, CD19, CD34, CD45, cMPO, and nTdt (9 markers).

Flow Cytometry
B-ALL Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are cCD3, CD5, CD10, CD11c, CD19, CD20, cCD22, CD23, CD34, CD45, cCD79a, kappa, lambda, cMPO, and nTdT (15 markers).

Flow Cytometry
B-ALL MRD Flow Panel

Available as global test only. Markers are CD3, CD9, CD10, CD13/CD33, CD19, CD20, CD34, CD38, CD45, CD58, CD71, and Syto16 (13 markers; Syto16 is not reported). This panel can detect MRD at the 0.01% level.

Flow Cytometry
B-Cell Gene Rearrangement

Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.

Molecular
B-Cell Lymphoma Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are CD5, CD10, CD11c, CD19, CD20, CD23, CD45, FMC-7, kappa, and lambda.

Flow Cytometry
BCL1 Translocation, t(11;14)

Real-time PCR for quantitative detection of t(11;14) BCL1/IgH rearrangements. Analytical sensitivity is approximately 1 tumor cell in 1000 normal cells. Positive results are reported as a ratio between quantities of (11;14) DNA and a normal control gene. This translocation is also known as CCND1/IgH or BCL1/JH.

Molecular
BCL1/Cyclin D1BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by mediating the growth stimulatory effects of hormone receptor signaling. It has been found to play a major role in both breast and prostate tumorigenesis. Nuclear overexpression of BCL1 has been shown to increase the chance of prostate cancer metastasis to bone, and has been associated with poor prognosis. High nuclear expression of BCL1 is usually associated with poor prognosis. Immunohistochemistry (IHC)
BCL10

BCL-10 is an N-terminal CARD (Caspase Recruitment Domain) containing protein that is involved in the adaptive immune response. It is also a substrate for MALT1. Mutations in the gene can lead to lymphoma, mucosa-associated lymphoid type. It is useful in the assessment of pancreatic tumors to distinguish acinar cell carcinoma from primitive neuroectodermal tumor (PNET), solid pseudopapillary tumor (SPT) and pancreatic blastoma (PB).

Immunohistochemistry (IHC)
BCL2B-cell lymphoma 2 (BCL2) was the first of the translocation-associated proteins to be identified in lymphoma. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease progression. BCL2 is also expressed in a wide range of other neoplasms. Immunohistochemistry (IHC)
BCL2Probes: BCL2 (18q21)
Disease(s): B-cell lymphoma, non-Hodgkin lympoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)
FISH
BCL2 Translocation, t(14;18)

PCR and fragment analysis for quantitative detection of IGH-BCL2 translocations associated with 70-80% of follicular lymphoma and approximately 20% of diffuse large B-cell lymphoma. Translocations involving the major (MBR), minor (MCR), and 3' MBR sub-cluster regions of BCL2 are analyzed. Positive results quantify the ratio of mutant BCL2 to internal control DNA. Testing may be performed on plasma to increase sensitivity.

Molecular
BCL6BCL6 antibody stains the germinal center cells in lymphoid follicles, the follicular cells and interfollicular cells in follicular lymphoma, a subset of diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of Reed-Sternberg cells in nodular lymphocyte predominant Hodgkin lymphoma. In contrast, BCL6 rarely stains mantle cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma. BCL6 expression is seen in approximately half of CD30+ anaplastic large cell lymphomas but is absent in other peripheral T-cell lymphomas. Immunohistochemistry (IHC)
BCL6 (3q27)Probes: BCL6 (3q27)
Disease(s): Diffuse large B-cell lymphoma, NHL
FISH
BCR-ABL1 Non-Standard p230

Real-time RT-PCR for detection of t(9;22) BCR-ABL1 fusion transcripts that result in p230 fusion proteins. Analytical sensitivity is 1 tumor cell in 100,000 normal cells. BCR-ABL1 Standard p210, p190 may be ordered as a stand-alone test.

Molecular
BCR-ABL1 Standard p210, p190

Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (E13, E14) or minor p190 (E1) fusion proteins with option to add p230 detection (micro or atypical variant). p230 testing may be ordered as a stand-alone test. For p210 and p190, analytical sensitivity is 1 tumor cell in 100,000 normal cells, log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report. For p230, results are reported as percent abnormal. Testing is New York approved for p210 and p190 only.

Molecular
BCR/ABL1 t(9;22)

Probes: ABL1 (9q34); ASS1 (9q34; BCR (22q11.2)
Disease(s): CML, ALL, MPN
Note: For suspected ALL, STAT processing is available by request. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
BOB1BOB1 is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 staining is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma or T-cell histiocyte-rich large B-cell lymphoma (both markers expressed). Immunohistochemistry (IHC)
BRAF Mutation Analysis

Bi-directional sequencing of exon 15 of the BRAF gene, which includes qualitative detection of V600 mutations E, K, D, and others, plus other significant exon 15 mutations.  For solid tumors, tumor enrichment is performed before extraction. Expanded coverage for BRAF exons 11 & 15 is available in the RAS/RAF Panel. Testing is available separately or in combination with HRAS, KRAS, and NRAS in the RAS/RAF Panel. Testing is approved for specimens from the state of New York. 

Molecular
BRAF V600EA monoclonal antibody (VE1) against mutant BRAF (V600E) permits fast assessment of the mutant protein expression throughout a tumor sample in hairy cell leukemia, some melanomas, and some thyroid carcinomas. BRAF mutation is a strong molecular marker of poor prognosis in colorectal carcinoma (CRC), and can be used as evidence of a sporadic mechanism of mismatch repair deficiency. Immunohistochemistry (IHC)
BTK Inhibitor Acquired Resistance Panel

Concurrent bi-directional sequencing of hotpost regions in the BTK and PLC-gamma-2 genes. Analysis includes the BTK mutation C481S and surrounding regions corresponding to amino acids C464 to M509 and the following PLC-gamma-2 mutations and surrounding regions: R665W (W646 to S679), S707 (A681 to M743), and L845F (I839 to V860).

Molecular
BTK Inhibitor Primary Susceptibility Panel

Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P mutation.

Molecular
BTK Mutation Analysis

Bi-directional sequencing to detect the C481S mutation in exon 15 and other potential mutations within the amino acid range C464 to M509. Testing is available separately or in combination with PLC-gamma-2 in the BTK Inhibitor Acquired Resistance Panel. NeoGenomics recommends ordering the combination Panel.

Molecular
CALR Mutation Analysis

Bi-directional sequencing of exon 9 of the CALR (calreticulin) gene with fragment length analysis for enhanced detection of low levels of insertion/deletion mutations.Testing is approved for specimens from the state of New York. Read more about the CALR Mutation Analysis.

Molecular
CBFB inv(16)Probes: CBFB inv(16), t(16;16)
Disease(s): AML, AMML (AML-M4E)
FISH
CBL Mutation Analysis

Bi-directional sequencing of exons 8 and 9 of the CBL gene.

Molecular
CCND1(BCL1)/IgH t(11;14)Probes: CCND1/IgH t(11;14)
Disease(s): Mantle cell lymphoma, NHL
FISH
CD10CD10, also known as Common Acute Lymphocytic Leukemia Antigen (CALLA), is expressed in early lymphoid progenitors and normal germinal center cells. It is almost always present on the surface of precursor B-lymphoblastic and Burkitt lymphomas and much less frequently on precursor T-lymphoblastic leukemia-lymphoma. Many follicular lymphoma and some diffuse large B-cell lymphomas, along with multiple myeloma are positive. CD10 is also present on breast myoepithelial cells, bile canaliculi, fibroblasts and with especially high expression on the brush border of kidney and gut epithelial cells. CD10 is also a good marker of endometrial stomal sarcoma. Immunohistochemistry (IHC)
CD11cIn normal cells, CD11c is expressed on activated CD4/CD8+ T cells, granulocytes, lymphocytes, macrophages, and NK cells.

In diseased, cells, CD11c is detected on acute myeloid leukemia (AML)-M4 and M5, hairy cell leukemia, lymphoplasmacytic lymphoma (81%), small lymphocytic lymphoma (SLL), splenic lymphoma, Langerhans cell histiocytosis, sinus histiocytosis, psoriatic skin lesions, and some follicular lymphomas.
Immunohistochemistry (IHC)
CD123CD123 labels plasmacytoid dendritic cells and is useful in diagnosing neoplasms derived from these cells as well as reactive conditions, such as histiocytic necrotizing lymphadentis. Immunohistochemistry (IHC)
CD138CD138 (Syndecan-1) positively stains normal tissue including B-cell precursors and plasma cells. Positive staining in tumors includes myeloma, primary effusion lymphoma. CD138 negative staining comprises mature B-cells and lymphomas (even plasmacytoid lymphomas). Many carcinomas also express CD138. Immunohistochemistry (IHC)
CD14CD14 stains normal macrophages/monocytes, granulocytes (weak), Langerhans cells, dendritic cells, and B cells. Positive staining in diseased cells comprises B-cell chronic lymphocytic leukemia (B-CLL), follicular center cell lymphoma, diffuse large B cell lymphoma (DLBCL), and acute myeloid leukemia (AML)-M4/M5. Immunohistochemistry (IHC)
CD15CD15 (X-Hapten) plays a role in mediating phagocytosis, bactericidal activity, and chemotaxis. It is present on granulocytes, including neutrophils and eosinophils, and to a lesser degree on monocytes. CD15 is also expressed in Reed-Sternberg cells and some epithelial cells. CD15 antibody is useful in the identification of Hodgkin lymphoma. CD15 is occasionally expressed in large cell lymphomas of both B- and T- phenotypes. Immunohistochemistry (IHC)
CD163CD163 antigen is restricted in its expression to the monocytic/macrophage lineage. It is present on all circulating monocytes and most tissue macrophages except those found in the mantle zone and germinal centers of lymphoid follicles, interdigitating reticulum cells and Langerhans cells. Immunohistochemistry (IHC)
CD19CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. Immunohistochemistry (IHC)
CD1aAt least five CD1 genes (CD1a, b, c, d, and e) have been identified. CD1a is expressed on cortical thymocytes, Langerhans cells, and dendritic cells. It is absent on mature peripheral blood T-cells, but cytoplasmic expression is detected on activated T-lymphocytes. CD1a is found on a subset of T-lymphoblastic lymphoma-leukemia and cases of Langerhans cell histiocytosis. Immunohistochemistry (IHC)
CD2CD2, the E-rosette receptor, is an extremely broad T-cell marker. This antibody immunostains the vast majority of T-cells and a subset of natural killer (NK) - cell malignancies. Half of thymic B-cells are also CD2 positive. Immunohistochemistry (IHC)
CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas. Immunohistochemistry (IHC)
CD21CD21 (CR2, C3d receptor and EBV receptor) is expressed strongly on mature B-cells, follicular dendritic cells (FDC) and weakly on immature thymocytes and T-lymphocytes. In B-cell ontogeny, CD21 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. Immunohistological analysis of FDC in paraffin sections of Non-Hodgkin lymphoma (NHL) with this antibody demonstrates a nodular and usually dense and sharply defined FDC meshwork in follicular lymphomas and a loose, ill-defined FDC of varying size in some diffuse lymphoma types. Precursor B-cell lymphoma (lymphoblastic lymphomas), Burkitt lymphomas, plasmacytomas and hairy cell leukemias consistently lack CD21 expression. CD21 is expressed on follicular dendritic cell sarcoma. Immunohistochemistry (IHC)
CD22CD22 expression is restricted to normal and neoplastic B-cells and is absent from other hemopoietic cell types. In B-cell ontogeny, CD22 is first expressed in the cytoplasm of pro-B and pre-B-cells and on the surface as B-cells mature to become IgD+. It is not expressed by plasma cells. CD22 is found highly expressed in follicular, mantle and marginal zone B-cells, while germinal center B-cells are relatively weak. Its expression roughly parallels that of CD19. It is strongly expressed in hairy cell leukemia. Immunohistochemistry (IHC)
CD23CD23 is identical to low affinity IgE receptor found on B-cells. CD23 is expressed on a subpopulation of peripheral blood cells, B-lymphocytes and on EBV transformed B-lymphoblastoid cell lines. CD23 is most useful in distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from other entities and may remain present in CLL/SLL that has undergone large cell transformation. Immunohistochemistry (IHC)
CD25The interleukin-2 receptor is designated CD25. Originally isolated from T-lymphocytes, it is now known to be expressed on hairy cell leukemia and adult T-cell leukemia/lymphoma, classical Hodgkin lymphoma, and a subset of other peripheral T-cell lymphomas. Immunohistochemistry (IHC)
CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. Immunohistochemistry (IHC)
CD30CD30 is a lymphocyte activation antigen, related to tumor necrosis factor. It is expressed in activated B-, T- and NK cells. Positive staining is seen in infectious mononucleosis, lymphocytes infected with HIV, HTLV-1, EBV, HHV8 or hepatitis B, Reed-Sternberg cells, anaplastic large cell lymphomas (90%), lymphomatoid papulosis, peripheral T-cell lymphomas, and embryonal cell tumors. Immunohistochemistry (IHC)
CD33CD33 is a useful marker to identify cells of myeloid and monocytic lineage, leukemias and myeloproliferative neoplasms derived from these cells. Immunohistochemistry (IHC)
CD34CD34, a single chain transmembrane glycoprotein, is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and endothelial cells. CD34 antibody labels many gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, solitary fibrous tumor and a subset of sarcomas. CD34 staining has been also used to measure angiogenesis. Immunohistochemistry (IHC)
CD38CD38 is a transmembrane protein that is highly expressed on thymocytes. It is also present on activated T-cells and terminally differentiated B-cells (plasma cells). Other reactive cells include NK cells, monocytes, macrophages and dendritic cells. CD38 may be detected on cells from multiple myeloma, acute lymphoblastic leukemia (ALL, B and T) and some acute myeloid leukemia (AML). Immunohistochemistry (IHC)
CD4CD4, a single chain transmembrane glycoprotein, is found on a T-cell subset (helper/inducer). It is also present on a variety of monocyte-derived cells, including Langerhans and other dendritic cells. The CD4 epitope is absent from immature thymocytes and is expressed during T-cell development. Precursor T-lymphoblastic lymphomas are therefore variable in their expression of CD4, but most mature T-cell lymphomas are positive, with the exception of aggressive NK-cell leukemia, extranodal NK-cell lymphoma, gamma delta T-cell lymphomas, and enteropathy-type T-cell lymphoma. Immunohistochemistry (IHC)
CD42bCD42b stains normal platelets, megakaryocytes, and megakaryoblasts. In diseased cells, blasts in transient myeloproliferative disorder are positively stained. CD42b is used in diagnosis of acute myeloid leukemia (AML)-M7, distinguishing AML-M7 (CD42b+) from acute myelosis with myelofibrosis (usually CD42b negative). Immunohistochemistry (IHC)
CD43CD43 (leukosialin, sialophorin, or leukocyte sialoglycoprotein) is a cell surface glycoprotein that is expressed on all thymocytes, T-cells, and cells of myeloid lineage. CD43 antibody can be useful in the diagnosis of T-cell lymphoma and a subset of B-cell lymphoma. CD43 expression in lymphomas is highly correlated with CD5; thus, most T-cell malignancies and a group of small lymphocyte B-cell malignancies (CLL/SLL, mantle cell lymphoma, and prolymphocytic leukemia (PLL)) are often positive, whereas follicular lymphoma is rarely positive. CD43 is also positive in about 50% of cases of Burkitt lymphoma. Immunohistochemistry (IHC)
CD43/FMC-7 Companion Add-On Flow PanelAvailable as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD43, CD3, CD22, CD36, FMC-7 and CD45 (6 abs).
CD45 (LCA)CD45 (Leukocyte Common Antigen, LCA) is comprised of at least four isoforms (CD45RA, CD45RB, CD45RC and CD45RO) of membrane glycoproteins. CD45 is expressed on hematopoietic cells (human leukocytes, including lymphocytes, monocytes, and eosinophils), but is absent on normal and malignant non-hematopoietic tissues. Immunohistochemistry (IHC)
CD45ROCD45RO (an isoform of leukocyte common antigen) reacts with mature activated T-cells, most thymocytes, and a sub-population of resting T-cells within both CD4 and CD8 subsets. CD45RO antibody marks many T-cell lymphomas but also identifies granulocytes, histiocytes and some B-cells. It rarely stains B-cell lymphomas. Immunohistochemistry (IHC)
CD5CD5, a transmembrane protein, is found on most thymocytes and immature peripheral T-cells. It stains normal B-cells of mantle zone of spleen and lymph nodes, B-cells in peritoneal and pleural cavities, and almost all T-cells. In a fetus, most B-cells in spleen and cord blood are CD5 positive. It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma. Immunohistochemistry (IHC)
CD56CD56 recognizes two proteins of the neural cell adhesion molecule, the basic molecule expressed on most neuroectodermally-derived cell lines, tissues and neoplasms (e.g. retinoblastoma, medulloblastomas, astrocytomas, and neuroblastomas). It is also expressed on some mesodermally-derived tumors (rhabdomyosarcoma) and on natural killer cells. CD56 can be used as a marker for NK cell neoplasms. Some benign and malignant plasma cells are also positive. CD56 is often positive in neuroendocrine carcinomas. Immunohistochemistry (IHC)
CD57CD57 is expressed on subpopulations of peripheral blood mononuclear cells, NK active cells and T-cells. Hematopoietic malignancies that are CD57+ include a minority of T-lymphoblastic leukemias, roughly three quarters of the indolent T-cell large granular lymphocytic leukemias, and a small portion of NK-cell lymphomas. It can be used to highlight small lymphoid cells in nodular lymphocytic predominant Hodgkin lymphoma. Immunohistochemistry (IHC)
CD61CD61 (GPIIIa) is a glycoprotein found on megakaryocytes, platelets, and their precursors. CD61 antigen plays a role in platelet aggregation and also as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectrin. This antibody is useful in detecting neoplastic platelet precursors, normal platelets, and most cases of megakaryocytic leukemias. Immunohistochemistry (IHC)
CD68CD68 is an antibody directed against lysosomes. It is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, lamina propria of the gut, lung alveoli, and bone marrow. This antibody reacts with myeloid precursors and peripheral blood granulocytes. It shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with true histiocytic neoplasia. It also stains granular cell tumors and some cases of melanoma, renal cell carcinoma, and pleomorphic sarcoma. Tumors of lymphoid origin are usually not stained. Immunohistochemistry (IHC)
CD7CD7 is expressed on the majority of immature and mature T-lymphocytes and T-cell leukemia. It is also found on natural killer cells, and a small subpopulation of normal and malignant B-cells. CD7 antibody can be useful for detection of T-cell leukemias and myeloid leukemias. CD7 expression is often lost in mycosis fungoides. Immunohistochemistry (IHC)
CD71CD71 is useful in identifying erythroid precursors with no interference from mature erythrocytes and also in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome. Immunohistochemistry (IHC)
CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. Immunohistochemistry (IHC)
CD79B Mutation Analysis

Bi-directional sequencing of exon 5 of the CD79B gene which includes detection of the common Y196 mutations. Testing is available separately or as part of the NeoTYPE™ Lymphoma Profile.

Molecular
CD8CD8 is a T-cell marker for the detection of cytotoxic/suppressor T-cells. CD8 is also detected on NK cells, most thymocytes, a subpopulation of null cells, and bone marrow cells. This antibody is useful in evaluating T-cell lymphomas. Immunohistochemistry (IHC)
CD99CD99 (MIC2 gene product, E2) antigen is strongly expressed by Ewing sarcoma cells, primitive peripheral neuroectodermal tumors, and lymphoblastic leukemia/lymphoma. Immunohistochemistry (IHC)
CDKN2A (p16) Deletion FISH for ALL

Probes: CDKN2A (p16) (9p21) | Centromere 9
Disease(s): Acute Lymphoblastic Leukemia (ALL)

FISH
Chromosome Analysis

A wide variety of abnormalities can be identified, providing both diagnostic and prognostic information. Acute leukemias, lymphomas and chronic myeloid and lymphoid disorders are examined cytogenetically in order to establish the exact nature of the acquired genetic change. Rearrangements, also known as translocations, inversions, and deletions, can usually be detected under a light microscope. In most leukemias and lymphomas, changes in chromosome number (ploidy) or chromosome structure (rearrangements) are often observed.
 

Cytogenetics
CLL FISH PanelProbes: 6q- [SEC63 (6q21), MYB (6q23)] | ATM (11q22.3) | p53 (17p13.1) | Trisomy 12 (Cen 12) | 13q-/-13 (13q14, 13q34) | CCND1/IgH t(11;14) | Probes may be ordered separately (except 12 and 13 are tested together, and ATM is tested with p53).
Disease(s): Chronic lymphocytic leukemia
Note: This test was previously called CLL FISH Panel (non-New York). It is now New York state-approved and available to all clients.
FISH
CLL MRD Flow Panel

Available as global test only. Markers are CD3, CD5, CD19, CD20, CD22, CD43, CD45, CD79b, and CD81 (9 markers).

Flow Cytometry
CLL/Mantle Cell Companion Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD3, CD22, CD36, CD43, CD45, CD200, and FMC7 (7 markers). This panel is not for detection of minimal residual disease (MRD).

Flow Cytometry
cMETThe cMET tyrosine kinase receptor, normally expressed by epithelial cells, is overexpressed and amplified in a variety of human tumors, including non-small cell lung carcinoma (NSCLC). High levels of intratumor cMET expression have been associated with a more aggressive biology and a worse prognosis in NSCLC. Engelman et al. reported that cMET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line. Moreover, cMET inhibition with a cMET tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity. Immunohistochemistry (IHC)
cMyccMyc protein is a transcription factor localized to the nucleus of the cell. Amplification of the cMyc gene has been found in several types of human tumors.

cMyc is amplified in 20-30% of breast cancer cases and is associated with HER-2 amplification and poor outcome. In Burkitt’s lymphoma, 90% of tumors have translocation of cMyc or variants. cMyc protein (>50%) is seen in a subset of cases of diffuse large B-cell lymphoma (DLBCL) and is correlated with Myc rearrangement. It is also positive in radiation-associated angiosarcoma.

Immunohistochemistry (IHC)
cRELInactive cREL resides in the cytoplasm and translocates to the nucleus upon activation. Strong, homogeneous nuclear cREL staining has been observed in primary mediastinal large B-cell lymphoma whereas nuclear cREL expression is more variable in other forms of diffuse large B-cell lymphoma (DLBCL). Evaluation of cREL nuclear expression combined with germinal center B-cell (GCB) and non-GCB phenotyping by IHC may improve patient risk stratification in DLBCL. Immunohistochemistry (IHC)
CSF3R Mutation Analysis

Bi-directional sequencing of exons 14 and 17 of the CSF3R gene which includes detection of the common mutation T618I (also known as T595I).

Molecular
CXCL13

CXCL13 is useful marker in the diagnosis of angioimmunoblastic T-cell lymphoma

Immunohistochemistry (IHC)
CXCR4 Mutation Analysis

Bi-directional sequencing to detect nonsense, frameshift, and other mutations encoding the C-terminus of CXCR4. Analyzed range includes detection of the C1013G mutation and spans amino acids L301 to S352. Testing is available separately or in combination with three other contributory genes in the BTK Inhibitor Primary Susceptibility Panel.

Molecular
DesminDesmin is an intermediate filament protein of both smooth and striated muscles. Antibody to desmin reacts with striated (skeletal and cardiac) as well as smooth muscle cells. Anti-desmin antibody is useful in identification of tumors of myogenic origin. It reacts with leiomyosarcomas (smooth muscle) as well as rhabdomyosarcomas (striated muscle). Immunohistochemistry (IHC)
DNA Ploidy/Cell Cycle Analysis – Heme

Available as a global test only. DNA stain is DRAQ5™ to determine S-phase cell cycle fraction and DNA index as indicators of DNA ploidy in fresh leukemia or lymphoma specimens. Two markers will be added for gating; which specific markers are used depends on the phenotype of the abnormal population.
Phenotyping requirement: If concurrent tech-only or global flow immunophenotyping was not done at NeoGenomics, client must submit a flow report showing the immunophenotype of abnormal cells or a description of the immunophenotype.
Indication note: Samples are only accepted from hematopoietic neoplasms for this test. Please see DNA Ploidy/Cell Cycle Analysis – POC/Solid Tumors for other indications.

Flow Cytometry
DNMT3A Mutation Analysis

Bi-directional sequencing of exon 26, a mutation hotspot region containing R882 and other mutations. In hematological disease, testing may be performed on plamsa to increase sensitivity. For solid tumors, tumor enrichment is performed before extraction.

Molecular
DUSP22-IRF4 Rearrangement

Probes: DUPS22-IRF4 gene region at 6p25.3
Disease(s): Anaplastic Large Cell Lymphoma (ALCL), large B-cell lymphoma
 

FISH
EBER

This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV-associated Hodgkin lymphoma cases. Global interpretation is available on head and neck specimens only; tech-only testing is available for all samples.

In Situ Hybridization (ISH)
EBV (LMP1)This antibody reacts strongly with Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with some EBV-associated neoplasms, particularly EBV-associated Hodgkin lymphoma. Immunohistochemistry (IHC)
EMAEpithelial Membrane Antigen (EMA) antibody stains normal and neoplastic cells from various tissues, including mammary epithelium, sweat glands and squamous epithelium. Hepatocellular carcinoma, adrenal carcinoma and embryonal carcinomas are consistently EMA negative, therefore, keratin positivity with negative EMA favors one of these tumors. EMA is frequently positive in meningioma, which can be useful when distinguishing it from other intracranial neoplasms, e.g. Schwannomas. The absence of EMA can also be of value since negative EMA is characteristic of tumors such as adrenal carcinoma, seminomas, paraganglioma and hepatoma. Immunohistochemistry (IHC)
Eosinophilia FISH PanelProbes: PDGFRa, CHIC2, FIP1L1 (4q12) | PDGFRb (5q33) | FGFR1 (8p11) | CBFB inv(16), t(16;16) | Probes may be ordered separately.
Disease(s): Lymphoid and myeloid neoplasms with eosinophilia, including: Chronic eosinophilic leukemia, eosinophilia, MPN, AML-NOS, lymphoblastic lymphoma, CMML, AML with inversion 16
FISH
Erythroid-Mega Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD41, cCD61, CD13, CD34, CD45, CD71,  CD117, and CD235a (8 markers).

Flow Cytometry
ETV6 Mutation Analysis

Bi-directional sequencing of exons 2-7 of the ETV6 gene (formerly called TEL). This assay detects sequence variants rather than ETV6 translocations.

Molecular
ETV6-RUNX1 (TEL-AML1) Translocation, t(12;21)

Real-time RT-PCR for quantitative detection of the t(12;21) ETV6-RUNX1 fusion transcript (formerly called TEL-AML1). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results are reported as a percentage ratio between quantities of transcript of t(12;21) and the sum of t(12;21) plus a control gene.

Molecular
Extended Leukemia/Lymphoma Panel - 31 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD41, CD45, CD56, CD64, CD71, CD117, CD138, CD235a, FMC-7, HLA-DR, kappa, and lambda.

Flow Cytometry
EZH2 Mutation Analysis

Bi-directional sequencing of exons 3-13 and 15-18 of the EZH2 gene.

Molecular
Factor VIII RAFactor VIII-related antigen is a component of Factor VIII complex. Factor VIII-related antigen is one of the available immunohistochemical markers of endothelial cells. It has also been demonstrated in platelets and megakaryocytes. IHC staining of Factor VIII-related antigen is useful for diagnosis of vascular neoplasms and for identification of vascular invasion by neoplasms. Immunohistochemistry (IHC)
FascinHuman fascin is a highly conserved actin-bundling protein. It is expressed predominantly in dendritic cells. Lymphoid cells, myeloid cells and plasma cells are negative for staining. However, Reed-Sternberg cells in Hodgkin lymphoma are positive for fascin staining. Epstein-Barr virus may induce expression of fascin in B-cells. Immunohistochemistry (IHC)
FGFR3/IgH t(4;14)Probes: FGFR3/IgH t(4;14)
Disease(s): Multiple myeloma, MGUS
FISH
FLT3 Mutation Analysis

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bi-directional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing may be performed on plasma to increase sensitivity.

Molecular
FOXP1FOX P1 (Forkheadbox-P1) is a transcription factor widely expressed in normal tissues. Its expression is commonly deregulated in malignancies. FOX P1 is differentially expressed in resting and activated B cells. FOX P1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCL) and is more common in the non-germinal center (non-GC), activated B-cell type. Loss of FOX P1 expression has been correlated with a poor prognosis in solid tumors, such as breast cancer. In contrast, high level expression of smaller isoforms of the FOX P1 protein identifies high risk patients with DLBCL. The study demonstrated a correlation between strong nuclear positivity and poor prognosis in a subset of patients with BCL2-positive, [t(14;18)]-negative, non-GC DLBCL. Immunohistochemistry (IHC)
GCET1The GCET1 gene codes for a serpin expressed in germinal center (GC) B-cells. GCET1 is highly restricted to a subset of GC B-cells and GC-derived lymphomas. It is preferentially expressed in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with GC B-cell differentiation. Immunohistochemistry (IHC)
Glycophorin AGlycophorin A (sialoglycoprotein alpha) is one of two transmembrane proteins exposed on the outer surface of normal human erythrocytes. This monoclonal antibody reacts with an epitope located on the extracellular domain of glycophorin A and does not cross-react with glycophorin D (glycophorin delta). In normal human erythrocytes, glycophorin A is expressed during all stages of differentiation, from the normoblast to the mature erythrocyte. Once maximally expressed, the quantity of glycophorin A in each red blood cell remains constant. Glycophorin A has also been located in the blast cells of cases of erythroleukemia. Cases of acute lymphoblastic and myeloblastic leukemia are not reactive. Immunohistochemistry (IHC)
Granzyme BGranzyme B antibody labels activated human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. This marker can be a useful tool for the identification of anaplastic large cell lymphoma, large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, and subcutaneous panniculitic T-cell lymphomas of T or NK phenotype. Immunohistochemistry (IHC)
Hairy Cell Leukemia (HCL) Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD11c, CD19, CD20, CD22, CD25, CD45, CD103, kappa, and lambda (9 markers).

Flow Cytometry
Hematogone Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD10, CD19, CD20, CD22, CD34, CD38, CD43, CD45, and cTdT (9 markers).

Flow Cytometry
Hemoglobin AHemoglobin A antibody reacts with the alpha chain of adult hemoglobin A. This antibody is useful in the detection of red blood cell precursors. Immunohistochemical localization of hemoglobin is excellent as an erythroid marker for the detection of immature, dysplastic, and megaloblastic erythroid cells in myeloproliferative disorders, such as erythroleukemia. In contrast, myeloid cells, lymphoid cells, plasma cells, histiocytes, and megakaryocytes stain negative with anti-hemoglobin A. Anti-hemoglobin A, combined with antibodies against CD34, CD117, CD68, and MPO can be helpful in distinguishing between reactive extramedullary hematopoiesis and that seen in neoplastic myeloid disorders in spleen. Anti-hemoglobin A is limited to expression by erythroid precursors in bone marrow and is therefore of assistance in calculating percentages of erythroid precursors. Immunohistochemistry (IHC)
Hereditary Cancer Susceptibility for Pediatrics

The Hereditary Cancer Susceptibility for Pediatrics panel is a sequencing based assay that can detect mutations in the entire coding region of the following genes listed. ALK, APC, BRCA1, BRCA2, CDH1, KRAS, MSH2, MSH6, NF1, NF2, NRAS, PALB2, PMS2, PTCH1, RB1, RET, RUNX1, SDHA, SDHB, TP53, and VHL. Note: Parent and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
HGALHGAL is specifically expressed in the cytoplasm of germinal center B-cells, but is absent in mantle and marginal zone. This antibody is highly specific for germinal center B-cells and it is an ideal marker for the detection of germinal center-derived B-cell lymphomas. Immunohistochemistry (IHC)
High Sensitivity PNH Evaluation

Markers are CD14, CD15, CD24, CD45, CD59, CD64, CD235a (Glycophorin A), and FLAER. In validation studies, this assay was shown to detect RBC and granulocyte PNH clones with frequency down to 0.01%.

Flow Cytometry
High-Grade B-Cell Lymphoma Reflex FISH Panel (Non-New York)

Probes: MYC (8q24). If rearranged, reflex to concurrent BCL2 (18q21) and BCL6 (3q27).
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

Note: This test is available on a global basis. Tech-only clients may order probes individually.

FISH
High-Grade/Large B-Cell Lymphoma Panel (NY and non-NY)

Probes: BCL6 (3q27) | MYC (8q24) | IgH/BCL2 t(14;18) | Optional probes: MYC/IgH/CEN8 t(8;14) [available to all clients] and BCL2 (18q21) [non-New York clients only]
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

FISH
HLADRThis antibody to the humn leukocyte antigen (HLA) MHC class II surface antigen stains a variety of cells expressing the HLADR antigen including B-lymphocytes, macrophages and dendritic cells. HLADR antibody is useful in the differentiation of lymphomas and leukemias and it discriminates most B-cell derived lymphomas from those of T-cell origin. Immunohistochemistry (IHC)
IDH1 & IDH2 Mutation Analysis

Bi-directional sequencing of the exon 4 mutation hotspot regions in both the IDH1 and IDH2 genes. IDH1 and IDH2 are analyzed concurrently. In hematological disease, testing may be performed on plasma to increase sensitivity. For solid tumors, tumor enrichment is performed before extraction.

Molecular
IgAIgA antibody reacts with immunoglobulin Ig alpha chains. It is useful in identifying leukemias, plasmacytomas and B-cell lineage lymphomas. Immunohistochemistry (IHC)
IgDIgD antibody reacts with immunoglobulin Ig delta chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas (in particular marginal zone lymphoma). Cytoplasmic staining is easily identified on paraffin tissue. IgD staining is also seen in normal mantle zone B-lymphocytes. Immunohistochemistry (IHC)
IgGIgG antibody reacts with immunoglobulin Ig gamma chains. This antibody may be useful in identifying plasma cytomas and B-cell lineage lymphomas, and in conjunction with IgG4 staining to assess for IgG4 associated disease. Immunohistochemistry (IHC)
IgH (14q32)

Probes: IgH (14q32)
Disease(s): Lymphoma, NHL, multiple myeloma, MGUS

FISH
IgH Clonality/MRD by NGS

The IgH Clonality/MRD by NGS assay detects clonal populations of B-lymphocytes in a given patient sample through the analysis of the VDJ segment of the immunoglobulin heavy chain (IgH) gene. *Note - Baseline testing of the original primary sample will need to be performed prior to testing on new samples submitted for monitoring of minimal residual disease.

Molecular
IgH/BCL2 t(14;18)Probes: IgH/BCL2 t(14;18)
Disease(s): Follicular lymphoma, NHL
FISH
IgH/MAF t(14;16)Probes: IgH/MAF t(14;16)
Disease(s): Multiple myeloma, MGUS
FISH
IgH/MAFB t(14;20)

Probes: IgH/MAFB t(14;20)
This probe combination may be ordered separately or added to any of our mye
Disease(s): Myeloma, MGUSloma FISH panels.

FISH
IgM

IgM antibody reacts with immunoglobulin Ig mu chains. This antibody is useful when identifying leukemias, plasmacytomas and B-cell lineage lymphomas.

Immunohistochemistry (IHC)
IgVH Mutation Analysis

RT-PCR and bi-directional sequencing of the variable region of the immunoglobulin heavy chain for detection of mutation from germline sequence. The mutated VH gene family is identified in positive reports (>3% sequence deviation). Mutation may not be detectable in specimens containing <10% clonal B-cells.

Molecular
inv(16), CBFB-MYH11 Translocation

Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript. Positive results are reported as ratio of the amount of fusion transcript with the amount of transcript from a normal control gene. This assay identifies type A fusions, which account for >90%. Analytical sensitivity is 1 tumor cell in 100,000 normal cells.

Molecular
JAK2 Exon 12-14 Mutation Analysis

RT-PCR and bi-directional sequencing to detect non-V617F mutations in exons 12-14 and most of exon 15, corresponding to the majority of the JAK2 pseudokinase domain. Exon deletion mutations are detectable. Testing is performed on plasma for increased sensitivity whenever possible. V617F analysis is recommended before or concurrently with this test. Exon 12-14 Mutation Analysis may be ordered separately, with concurrent V617F testing, by reflex after negative V617F testing, or as part of the MPN Reflex Panel. Testing is approved for specimens from the state of New York.

Molecular
JAK2 V617F Mutation Analysis

Detects the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered separately, concurrently with full exon 12-14 sequencing, with reflex to exon 12-14 sequencing, or as part of the MPN Reflex Panel. Testing is approved for specimens from the state of New York.

Molecular
KappaAntibody to the kappa light chain of immunoglobulin is reportedly useful in the identification of leukemias, plasmacytomas and certain non-Hodgkin lymphomas. Demonstration of monotypism in lymphoid infiltrates is a surrogate for clonality, and therefore malignancy. Immunohistochemistry (IHC)
KappaEach test contains a set of oligonucleotide probes. The intended target is the kappa light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations. In Situ Hybridization (ISH)
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Note: Computer-assisted image analysis for Ki-67 is only validated for breast cancer and neuroendocrine carcinoma.

Immunohistochemistry (IHC)
Lambda

Each test contains a set of oligonucleotide probes. The intended target is the lambda light chain immunoglobulin messenger RNA (mRNA) in the cytoplasm of immunoblastic cells, plasma cells and plasmacytoid cells. Assessing the light chain immunoglobulin restriction is important in malignant lymphoma diagnosis. The relationship between monoclonal B-cell proliferation and light chain mRNA restriction aids in the distinction between neoplastic and reactive lymphoid proliferations and the evaluation of multiple myeloma, plasmacytoma, lymphomas with plasmacytoid features, immunoblastic lymphomas and reactive plasma cell proliferations.

In Situ Hybridization (ISH)
LEF1LEF1 overexpression is highly associated with CLL/SLL among small B-cell lymphomas and may serve as a useful marker for diagnosis and differential diagnosis of the disease. Immunohistochemistry (IHC)
LMO2LMO2 protein is expressed in normal human germinal-center (GC) and GC-derived lymphomas. In addition, it is also expressed at high levels in endothelial cells, spleen, hematopoietic precursors, and a significant proportion of acute lymphoblastic and myeloid leukemias. In diffuse large B-cell lymphoma (DLBCL), LMO2 protein expression is aligned with GC markers HGAL, CD10 and BCL6, indicating a potential role for LMO2 in the prognostic stratification of DLBCL patients. It is rarely expressed in mature T, natural killer (NK) and plasma cell neoplasms and is absent from non-hematolymphoid tissues, except for endothelial cells. Immunohistochemistry (IHC)
Low-Grade/Small B-Cell Lymphoma FISH Panel

Probes: BCL6 (3q27) | CCND1/IgH t(11;14) IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes may be ordered separately.
Disease(s): NHL, B-Cell Lymphoma, MCL, follicular lymphoma, MZL, MALT lymphoma

FISH
LysozymeLysozyme is synthesized predominantly in reactive histiocytes rather than in resting, unstimulated phagocytes. This antibody labels myeloid cells, histiocytes, granulocytes, macrophages and monocytes. It is helpful in the identification of myeloid or monocytic nature of acute leukemia. Immunohistochemistry (IHC)
MAL

MAL is a distinct molecular marker of primary mediastinal large B-cell lymphoma subtype among diffuse large B-cell lymphomas.

Immunohistochemistry (IHC)
MALT1 (18q21)

Probes: MALT1 (18q21)
Disease(s): Marginal zone B-cell lymphoma, NHL

FISH
Mast Cell Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD2, CD25, CD34, CD45, and CD117 (5 markers).

Flow Cytometry
MDS Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD11b, CD13, CD36, CD41, CD45, CD71, CD117,  CD123, and CD235a (9 markers).

Flow Cytometry
MDS Extended FISH Panel

Probes: RPN1, MECOM (3q21, 3q26.2) | 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | ETV6 (12p13) | 17p- (TP53 17p13.1, NF1 17q11.2) | +19 (19p13.2, 19q13) | 20q- (20q12, 20qter)
Probes may be ordered separately except +8 and 20q- which are combined.
Disease(s): Myelodysplastic syndrome

FISH
MDS FISH Panel (New York)Probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (7q31, Cen 7) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter)
Probes may be ordered separately except +8 and 20q- which are combined.
Disease(s): Myelodysplastic syndrome
FISH
MDS Standard FISH PanelProbes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | Trisomy 8 (Cen 8) | MLL (11q23) | 20q- (20q12, 20qter)
Probes may be ordered separately except +8 and 20q- which are combined.
Disease(s): Myelodysplastic syndrome
FISH
MET (c-MET) Mutation Analysis

Bi-directional Sanger sequencing of MET is performed using PCR primers designed to target hotspot mutations in exons 14, 16, 17 and 19.

Molecular
MET FISHProbes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
FISH
MGMT Promoter Methylation Analysis

Bisulfite modification of tumor DNA and real-time PCR are used to quantify CpG methylation within the MGMT gene promoter. Percentage of methylated DNA (compared to total DNA) is reported for positive results.

Molecular
MLL (11q23)Probes: MLL (11q23)
Disease(s): ALL, AML
FISH
Monocyte Maturation Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers CD15, CD64, HLA-DR, CD13, CD11c, CD36, CD14, CD56, CD11b and CD45 (10 markers).

Flow Cytometry
MPL Mutation Analysis

Bi-directional sequencing of exon 10 of the MPL gene to detect all possible mutations at the W515 and S505 codons, and other mutations throughout the exon. Testing is performed on plasma for increased sensitivity whenever possible. This test may be ordered separately or as part of the MPN Reflex Panel.

Molecular
MPN Extended Reflex Panel

Sequential testing panel including analysis of JAK2 V617F, JAK2 Exon 12-14, CALR exon 9, and MPL exon 10. Testing proceeds by reflex through the four-step panel until a mutation is identified, when the result is considered informative and no further testing is performed. Testing is performed on plasma for increased sensitivity whenever possible. Tests may also be ordered individually or as a three-step reflex panel without CALR in the MPN Standard Reflex Panel (see separate listing). Testing is approved for specimens from the state of New York. 

Molecular
MPN FISH Panel

Probes: PDGFRa, CHIC2, FIP1L1 (4q12) | PDGFRb (5q33) | FGFR1 (8p11) | BCR/ABL1 t(9;22) including ASS1 (9q34) | Probes may be ordered separately.
Disease(s): Myeloproliferative neoplasms

FISH
MPN Standard Reflex Panel

Sequential testing panel including analysis of JAK2 V617F, JAK2 Exon 12-14, and MPL exon 10. Testing proceeds by reflex through the three-step panel until a mutation is identified, when the result is considered informative and no further testing is performed. Testing is performed on plasma for increased sensitivity whenever possible. Tests may also be ordered separately. For reflex testing including CALR mutation analysis, please see the separate listing for MPN Extended Reflex Panel. Testing is approved for specimens from the state of New York. 

Molecular
MPOMyeloperoxidase (MPO) is an important enzyme used by granulocytes during phagocytic lysis of engulfed foreign particles. In normal tissues and in a variety of myeloproliferative disorders, myeloid cells of both neutrophilic and eosinophilic types, at all stages of maturation, exhibit strong cytoplasmic reactivity for MPO. MPO is useful in differentiating between myeloid and lymphoid leukemias. Immunohistochemistry (IHC)
MPO Cytochemical

Cytochemical stain. Myeloperoxidase (MPO) is present in granules of myeloid and monocytic cells, but absent from lymphocytes. Therefore MPO is an important marker for discriminating myeloid vs. lymphoid blasts. Staining is used to distinguish acute myeloid leukemia (AML) and other myeloid leukemias from lymphoid disorders.

Immunohistochemistry (IHC)
Multiple Myeloma IgH Complex FISH Panel (New York)

Probes: FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | IgH/MAF t(14;16) | Probes for each translocation may be ordered separately.                      Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) testing unless directed otherwise by our client.

FISH
Multiple Myeloma-MGUS FISH Panel (New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | +3, hyperdiploidy (Cen 3) | +5, hyperdiploidy (5p15.2, 5q33-34) | +9, hyperdiploidy (Cen 9) | 13q- (13q14, 13q34) | IgH (14q32) | p53 (17p-)
Probes may be ordered separately except +3 and +9 which are combined.
Disease(s): Plasma cell myeloma, multiple myeloma, MGUS
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize p53 testing unless directed otherwise by our client.

FISH
MUM1The MUM1 antibody is specific for the MUM1/IRF4 protein that is overexpressed in late plasma-cell-directed stages of B-cell differentiation. MUM1 is a powerful tool for understanding the histogenesis of B-cell lymphomas. MUM1 protein is an excellent marker for Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma in combination with CD30. Furthermore, MUM1 seems to be a marker of prognostic value since it has been found that the expression of MUM1 is associated with the poor prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry (IHC)
MYC (8q24)Probes: MYC (8q24)
Disease(s): Lymphoma, NHL, B-ALL
FISH
MYC/IgH/Cen 8 t(8;14)Probes: Trisomy 8 (Cen 8) | MYC/IgH t(8;14)
Disease(s): Burkitt lymphoma, NHL
FISH
MYD88 Mutation Analysis

Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation.

Molecular
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Cytogenetics
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Molecular
NeoLAB™ AML Profile - Liquid Biopsy

This test is performed by sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. Test orders include summary interpretation of all results together. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoLAB™ MDS/CMML Profile- Liquid Biopsy.

Molecular
NeoLAB™ BTK Inhibitor Acquired Resistance Panel - Liquid Biopsy

The NeoLAB™ BTK Inhibitor Acquired Resistance Panel is a blood test performed by modified properietary bi-directional sequencing of the BTK and PLC-gamma-2 genes using cell-free circulating tumor DNA (ctDNA). This method allows detection of mutations with sensitivity of 10(-4). Analysis includes the BTK mutation C481S and surrounding regions corresponding to amino acids C464 to M509 and the following PLC-gamma-2 mutations and surrounding regions: R665W (W646 to S679), S707 (A681 to M743), and L845F (I839 to V860).

Molecular
NeoLAB™ FLT3 Mutation Analysis - Liquid Biopsy

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ IDH1 Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH1 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ IDH2 Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of the exon 4 mutation hotspot region in the IDH2 gene. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ inv(16), CBFB-MYH11 Translocation - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript using cell-free plasma DNA/RNA. This assay identifies type A fusions, which account for >90%

Molecular
NeoLAB™ KIT (c-KIT) Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of KIT exons 8, 9, 11, 13 and 17 for detection of activating mutations including the common mutation D816V. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ KRAS Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ KRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological diseases at this time.

Molecular
NeoLAB™ MDS/CMML Profile - Liquid Biopsy

This test is performed by the sequencing the entire coding regions of the genes listed using cell-free plasma DNA/RNA. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, and ZRSR2. Test orders include summary interpretation of all results together.

Molecular
NeoLAB™ Myeloid Disorders Profile - Liquid Biopsy

This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A (MLL), KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. Test orders include summary interpretation of all results together.

Molecular
NeoLAB™ NPM1 Mutation Analysis - Liquid Biopsy

PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Molecular
NeoLAB™ NRAS Mutation Analysis - Liquid Biopsy

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ NRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological diseases at this time.

Molecular
NeoLAB™ PML-RARA Translocation, t(15;17) - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript using cell-free plasma DNA/RNA. Both long and short isoforms of the fusion transcript are detected.

Molecular
NeoLAB™ RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) - Liquid Biopsy

Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO) using cell-free plasma DNA/RNA.

Molecular
NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile

The NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile is performed by the sequencing of select exons in the genes IDH1, IDH2, DNMT3A, TET2 and RHOA

Molecular
NeoTYPE AML Favorable-Risk Profile

This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid genes can be added-on.

Molecular
NeoTYPE AML Prognostic Profile

This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, STAG2, TET2, TP53 and WT1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing). For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

Molecular
NeoTYPE CLL Prognostic Profile

This test is performed by the sequencing the entire coding regions of the genes MYD88, NOTCH1, SF3B1, and TP53 plus IgVH Mutation Analysis and the CLL FISH Panel as noted. Test orders include summary interpretation of all results together. Individual genes from a validated list of genes can be added-on. Test orders include summary interpretation of all results together. FISH components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component.

Molecular
NeoTYPE JMML Profile

This test is performed by sequencing the entire coding regions of the genes listed. BRAF, CBL, CEBPA, FLT3, HRAS, JAK2 including V617F and Exons 12+14, JAK3, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, and SETBP1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE Lymphoma Profile

This test is performed by multiple methods to detect mutations in the following genes BCL1, BCL2, BRAF, CARD11, CD79B, EZH2, MYD88 and NRAS. The test is performed by sequencing the entire coding regions of the genes listed unless otherwise noted. BCL1/ IgH translocation t(11;14) is performed by real-time PCR and BCL2  t(14;18) is performed by fragment length analysis. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE MDS/CMML Profile

This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ASXL1, BCOR, BCORL1, BRAF, CBL, CEBPA, CUX1, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, and ZRSR2. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE MPN Profile

This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ABL1, ASXL1, BRAF, CALR, CEBPA, CSF3R, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KRAS, MPL, NPM1, NRAS, PDGFRA, PTEN, PTPN11, SETBP1, SRSF2, TET2, and U2AF1. CALR and FLT3 are performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE Myeloid Disorders Profile

This test is performed by the sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2 including V617F and Exons 12+14, JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. CALR and FLT3 are performed by multiple methods. Test orders include summary interpretation of all results together.

Molecular
Non-Hodgkin's Lymphoma (NHL) FISH Panel

Probes: ALK (2p23) | BCL6 (3q27) | MYC (8q24) | CCND1/IgH t(11;14) | IgH (14q32) | IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes may be ordered separately.
Disease(s): NHL

FISH
NOTCH1 Mutation Analysis

Bi-directional sequencing of exons 26, 27, and 34 is performed for detection of sequence variant mutations. Testing can be performed on plasma when adequate leukemic cells are not available.

Molecular
NPM1 MRD Analysis

NPM1 MRD Analysis is performed by PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations. Testing is performed on plasma with a PCR modification to improve sensitivity. The lower limit of detection of mutated NPM1 in this assay is 5 x 10^-3 (0.5%). Positive results are reported quantitatively if the percentage of mutated DNA is ≥1%, and they are reported qualitatively if ˂1%.    

Molecular
NPM1 Mutation Analysis

PCR and fragment analysis of exon 12 of the NPM1 gene to detect small insertion mutations specific to AML. Positive results are reported quantitatively as percent abnormal DNA. Testing may be performed on plasma to increase sensitivity.

Molecular
NRAS Exon 4 Mutation Analysis

Bi-directional sequencing of NRAS exon 4 is performed using PCR primers designed to target hotspot mutations in codons 117 and 146, among other regions in exon 4. Testing is available separately or in combination with BRAF, KRAS and HRAS in the RAS/RAF Panel.

Molecular
NRAS Mutation Analysis

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61.

Molecular
NUP98

Disease(s): Acute Myeloid Leukemia
Probes: NUP98 (11p15.4)

FISH
OCT2Octamer Binding Transcription Factor 2 (OCT2) is present in all B-cells expressing Ig. The combination of BOB1 and OCT2 stains is helpful in distinguishing between classical Hodgkin lymphoma (at least one marker negative) and nodular lymphocyte predominant Hodgkin lymphoma (both markers expressed). Classical Hodgkin lymphoma stains as BOB1-OCT2+ or BOB1+ OCT2-, while nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) or diffuse large B-cell lymphoma (DLBCL) stains BOB1+ OCT2+. Immunohistochemistry (IHC)
PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells. Immunohistochemistry (IHC)
PD1Programmed death-1 (PD-1) is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PD-1 is expressed by few B-cells, so anti-PD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells. PD-1 expression in angioimmunoblastic lymphoma lends further support to this model of T-cell oncogenesis, in which specific subtypes of T-cells may undergo neoplastic transformation and result in specific distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia. Programmed Death 1 (PD1) is expressed on most T-cells and a small subset of B-cells in the light zone of germinal centers and is a useful marker of angioimmunoblastic lymphoma. Immunohistochemistry (IHC)
PDGFRa Mutation Analysis

Bi-directional sequencing of exons 12 and 18 of the PDGFRA (platelet-derived growth factor alpha) gene. These exons are mutation hotspots that account for the majority of PDGFRA mutations detected in gastrointestinal stromal tumors (GISTs) including the common TKI-resistance mutation D842V. Solid tumor enrichment is performed before extraction.

Molecular
PDGFRA RearrangementProbes: PDGFRA | CHIC2 | FIP1L1 (4q12) Disease(s): Chronic eosinophilic leukemia, MPN FISH
PerforinPerforin is a protein found in cytoplasmic granules of cytotoxic T-lymphocytes (CTLs). CTLs bind to cells that express foreign antigens and induce them to lyse. Perforin expression is significantly induced in CD8 positive T-cells, but to lesser extent in gamma/delta T-cells and NK cells. This antibody may be of value in the detection of perforin in CTLs in severe cases of graft versus host disease, chronic renal rejection and peripheral T-cell lymphomas. In addition, perforin antibody may also be useful for the detection of NK cell lymphomas, all of which express the perforin protein. Immunohistochemistry (IHC)
Periodic Acid Schiff (PAS)- HEMESpecial stain. Immunohistochemistry (IHC)
Plasma Cell Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD19, CD20, CD38, CD45, CD56, CD117, CD138, cKappa, and cLambda (9 markers).

Flow Cytometry
Plasma Cell Myeloma FISH Panel (non-New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | +5, hyperdiploidy (5p15) | +9, hyperdiploidy (9q22) | +15, hyperdiploidy (15q22) | 13q- (13q14, 13q34) | IgH (14q32) | 17p- (TP53 17p13.1, NF1 17q11.2)
Probes may be ordered separately except +5, +9 and +15 which are combined.
Global cases with IgH rearrangement will automatically reflex to the Plasma Cell Myeloma IgH Complex FISH Panel unless client has opted out.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize p53 testing unless directed otherwise by our client.
 

FISH
Plasma Cell Myeloma IgH Complex FISH Panel (non-New York)

Probes: FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | IgH/MAF t(14;16) | IgH/MAFB t(14;20)
Probes for each translocation may be ordered separately. 
This panel is available separately or by reflex after the Plasma Cell Myeloma FISH Panel if it detects IgH rearrangement.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) testing unless directed otherwise by our client.

FISH
Plasma Cell Myeloma Prognostic FISH Panel (New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | FGFR3/IgH t(4;14) | CCND1/IgH t(11;14) | 13q- (13q14, 13q34) | IgH/MAF t(14;16) | 17p- (TP53 17p13.1, Cen 17) | Probes for each rearrangement may also be ordered separately.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) and TP53 testing unless directed otherwise by our client.

FISH
Plasma Cell Myeloma Risk Stratification FISH Panel (non-New York)

Probes: 1p-, 1q+, iso(1q): CDKN2C (1p32), CKS1B (1q21) | FGFR3/IgH t(4;14) | IgH/MAF t(14;16) | IgH/MAFB t(14;20) | 17p- (TP53 17p13.1, NF1 17q11.2) | Probes may be ordered separately.
Disease(s): Plasma cell myeloma, multiple myeloma
Note: Plasma cell enrichment will be performed on bone marrow or blood samples unless our client directs us otherwise. (Peripheral blood is not recommended as a screening specimen unless increased plasma cells are seen on blood smear.) Specimens should be received in our laboratory within 72 hours of collection. If enriched samples are insufficient to complete the whole panel, NeoGenomics will prioritize t(4;14) and 17p-testing unless directed otherwise by our client.
 

FISH
PLC-Gamma-2 Mutation Analysis

Bi-directional sequencing to detect mutations in exons 19, 20, and 24, covering amino acid ranges W646 to S679, A681 to M743, and I839 to V860. Testing is available separately or in combination with the BTK Inhibitor Acquired Resistance Panel. NeoGenomics recommends ordering the combination Panel.

Molecular
PML-RARA Translocation, t(15;17)

Real-time RT-PCR for quantitative detection of the t(15;17) PML-RARA fusion transcript. Both long and short isoforms of the fusion transcript are detected. Positive results identify the isoform and quantify it as a ratio with the amount of transcript from a normal control gene. Analytical sensitivity is 1 tumor cell in 100,000 normal cells.

Molecular
PML/RARA t(15;17)

Probes: PML/RARA t(15;17)
Disease(s): AML, APL (AML-M3)
Note: PML-RARA FISH is performed STAT when ordered as a stand-alone test (outside a panel). Note MD contact name and phone number to receive STAT results.

FISH
PPM1D Mutation Analysis

PPM1D (Protein Phosphatase, Mg2+/Mn2+ Dependent 1D) Mutation Analysis is performed by next-generation sequencing (NGS) of all coding regions of the PPM1D gene. Germline and somatic mutation testing is available. Note: For germline testing (blood sample), patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
PTPN11 Mutation Analysis

Bi-directional sequencing of exons 2-4 of PTPN11.

Molecular
PU.1PU.1 is a transcription factor that has been shown to be important for normal B-cell development. The absence of PU.1 results in a total block of B-cell development at the pre-pro stage. It is expressed in the myeloid lineage and in immature, as well as mature, B-lymphocytes, with the exception of plasma cells. Various lymphomas are also positive for this marker including the following: B-chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Burkitt lymphoma, diffuse large cell lymphoma, diffuse large B-cell lymphoma, T-cell rich B-cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma. PU.1 is not expressed by Reed-Sternberg and Hodgkin cells in classical Hodgkin disease (cHD) in contrast to lymphocyte predominant Hodgkin Disease (LPHD). Immunohistochemistry (IHC)
RHOA Mutation Analysis

Bi-directional sequencing of the gene RHOA. The locked nucleic acid (LNA) technique is used to increase detection sensitivity for the G17V mutation. Note - Available as stand-alone or as part of the NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile.

Molecular
RUNX1 Mutation Analysis

Bi-directional sequencing of exons 4-10 of the RUNX1 gene

Molecular
RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)

Real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results are reported as a ratio between quantities of (8;21) transcript and a normal control gene.

Molecular
RUNX1T1/RUNX1 (ETO/AML1) t(8;21)Probes: RUNX1T1/RUNX1 (ETO/AML1) t(8;21)
Disease(s): AML-M2
FISH
SETBP1 Mutation Analysis

Bi-directional sequencing of the SETBP1 exon 4 mutation hotspot (covering amino acids 823-941). The locked nucleic acid (LNA) technique is used to increase detection sensitivity for mutations at D868, G870, I871, and D880.

Molecular
Sezary T-Cell Add-On Flow PanelAvailable as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD3, CD4, CD5, CD7, CD8, CD19, CD26, CD43, and CD45 (9 markers). Flow Cytometry
SF3B1 Mutation Analysis

RT-PCR and bi-directional sequencing of exons 14-17 of the SF3B1 gene. More than 90% of reported mutations are detected in these exons. This test detects mutations present at 10-15% or more in a wild-type background.

Molecular
SMASmooth muscle actin antibody binds to smooth muscle cells and myoepithelial cells. It stains the muscularis propria and muscularis mucosae of the gastrointestinal tract, the uterine myometrium, medial layer of blood vessels, myoepithelial cells of salivary glands and other organs. The antibody does not stain skeletal and cardiac muscle, endothelium, connective tissue, epithelium or nerve. The antibody can be used to identify smooth muscle tumors (leiomyomas and leiomyosarcomas). Immunohistochemistry (IHC)
SOX11Nuclear protein expression of SOX-11 is highly associated with both cyclin D1-positive and negative mantle cell lymphoma (MCL). SOX-11 IHC is useful for identifying true cyclin D1-negative MCL and further defining pathologic features of CD5+ DLBCL. Routine use of anti-SOX-11 in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-negative blastoid MCL. SOX-11 can also be detected in some BL, LBL, and T-PLL, although the different morphological and phenotypic features of these malignancies allow easy recognition of the cases of cyclin D1-negative MCL. Immunohistochemistry (IHC)
SRSF2 Mutation Analysis

Bi-directional sequencing of the mutation hotspot region in exon 1 of the SRSF2 gene corresponding to amino acids 57-120.

Molecular
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
STAT3 Mutation Analysis

Bi-directional sequencing of STAT3 exons 13-21 encompassing the DNA binding and SH2 domains.

Molecular
T&B Tissue Flow Panel

Stand-alone test. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD34, CD38, CD45, CD56, kappa, and lambda (17 markers). 

Flow Cytometry
T-ALL Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD1a, CD3, CD7, CD11b, CD19, CD43, CD45, cMPO, and nTdT (9 markers).

Flow Cytometry
T-ALL Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are CD1a , CD2, CD3, cCD3, CD4, CD5, CD7, CD8, CD11b, CD19, CD38, CD43, CD45, CD56, cMPO, and nTDT (16 markers).

Flow Cytometry
T-Cell Receptor Beta Gene Rearrangement

This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be ordered concurrently with or after negative results in our T-Cell Receptor Gamma Gene Rearrangement assay for gamma gene rearrangements to improve TCR rearrangement detection by ~5% in T-cell leukemias/lymphomas. 

Molecular
T-Cell Receptor Gamma Gene Rearrangement

Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this gamma gene test.

Molecular
T-Cell Receptor/LGL Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD3, CD4, CD7, CD8, CD16, CD45, CD56, CD57, TCR alpha/beta, and TCR gamma/delta (10 markers).

Flow Cytometry
T-Cell Therapy Flow Panel

Available as global and tech-only. Available as stand-alone test (as described here) or as add-on to panels. Markers are CD3, CD4, CD7, CD8, CD25, CD26, CD30, CD45, CD52, and CD279 (10 markers).

Flow Cytometry
TauTau is important in establishing and maintaining neuronal morphology and is a major component of the neurofibrillary tangles (NFTs) characteristic of an Alzheimer's diseased brain. Tau is also expressed in epithelial cells, including breast tissue. Down-regulation of Tau expression in breast cancer cells increases sensitivity to paclitaxel. Tau may be used as a marker to select patients for paclitaxel therapy. High Tau expression in estrogen receptor (ER)-positive breast cancer indicates an endocrine-sensitive but chemotherapy-resistant disease. In contrast, low Tau expression identifies a subset of ER-positive cancers that have poor prognosis with tamoxifen alone and may benefit from taxane-containing hemotherapy. Immunohistochemistry (IHC)
TCL1Probes: TCL1 (14q32.1)
Disease(s): mature T-cell leukemia, T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/lymphoma (ATLL)
FISH
TCL1T-cell leukemia/lymphoma protein 1 (TCL1) is normally found in the nucleus and cytoplasm of lymphoid lineage cells during early embryogenesis. Chromosomal translocations may lead to overexpression of TCL1, resulting in T-cell leukemia and B-cell lymphoma. TCL1 is expressed in more differentiated B-cells, under both reactive and neoplastic conditions, from antigen committed B-cells and in germinal center B-cells. It is down-regulated in the latest stage of B-cell differentiation. The most useful application of TCL1 antibody is the discrimination of B-cell lymphomas from T-cell lymphomas, CD30+ anaplastic large cell lymphomas, multiple myeloma, and marginal zone B-cell lymphoma. Immunohistochemistry (IHC)
TET2 Mutation Analysis

Bi-directional sequencing of the entire coding sequence of the TET2 transcript variant A (2002 amino acids in length).

Molecular
Thrombomodulin (TM)Thrombomodulin (TM) is a plasma membrane-related glycoprotein that has anticoagulant activity. TM antigen is found in several cell types, including megakaryocytes, mesangial cells, synovial cells, mesothelial cells, endothelial cells, and some squamous epithelial cells and their associated tumors. TM antibody labels most mesotheliomas with thick membranous staining pattern and about half of pulmonary adenocarcinomas, showing cytoplasmic immunostaining. Thrombomodulin is also a marker of urinary bladder epithelium. Immunohistochemistry (IHC)
TIA1TIA1 (T-cell intracytoplasmic antigen) monoclonal antibody reacts with a 15 kDa cytoplasmic granule-associated protein, expressed in lymphocytes processing cytolytic potential. Most anaplastic large cell lymphomas react with TIA1. TIA1 also reacts with most large granular lymphocytic leukemias, hepatosplenic T-cell lymphomas, intestinal T-cell lymphomas, NK-like T-cell lymphomas, NK-cell lymphomas, nasal T/NK-cell lymphomas, subcutaneous T-cell lymphomas and pulmonary angiocentric lymphomas of T or NK phenotype. All B-cell lymphomas, Hodgkin and lymphoblastic leukemias are negative for TIA1. Immunohistochemistry (IHC)
TP53 Mutation Analysis

Bi-directional sequencing of TP53 exons 4-9.

Molecular
TPMT Genotyping

This PCR-based allele discrimination assay is performed on genomic DNA and detects the four most common abnormal alleles of the thiopurine methyltransferase (TPMT) gene, which are TPMT*2 (238G>C), TPMT*3A (460G>A + 719A>G), TPMT*3B (460G>A), and TPMT*3C (719A>G). The status of the abnormal alleles tested is reported as not detected, heterozygous, or homozygous. The TPMT enzyme activity associated with the genotype is reported as normal, intermediate, or low or no activity. The abnormal alleles tested in this assay account for >95% cases of low or undetectable TPMT enzyme activity.

Molecular
TrichromeSpecial stain. Trichrome stains are frequently used to differentiate between collagen and smooth muscle in tumors and to identify increases in collagenous tissue in diseases such as cirrhosis of the liver. Immunohistochemistry (IHC)
TryptaseThis antibody labels a mast cell tryptase. It will also show reactivity to basophils, but to a lesser degree. Immunohistochemistry (IHC)
Tumor Mutation Burden

Tumor Mutation Burden (TMB) testing at NeoGenomics measures the number of non-synonymous DNA coding sequence changes per megabase of sequenced DNA. Testing is performed routinely within the NeoTYPE™ Discovery Profile, can be added to any of the NeoTYPE Solid Tumor Profiles, and is available as a stand-alone test. Results are reported as low, high intermediate, and high upper quartile in reference to the median genomic TMB value determined across a wide variety of tumor types in an internal validation study. TMB is also called tumor mutational burden or tumor mutation load (TML). 

Molecular
U2AF1 Mutation Analysis

Bi-directional sequencing of exons 2 and 7 of the U2AF1 gene (also called U2AF35).

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
V-Beta T-Cell Clonality

Available as global test only. Markers are VB1, VB2, VB3, VB4, VB5.1, VB5.2, VB5.3, VB7.1, VB7.2, VB8, VB9, VB11, VB12, VB13.1, VB13.2, VB13.6, VB14, VB16, VB17, VB18, VB20, VB21.3, VB22, and VB23 (24 markers). Two additional T-cell markers are used to identify the population of interest and the markers vary from case to case.

Flow Cytometry
Wright GiemsaSpecial stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)
WT1 Mutation Analysis

Bi-directional sequencing of exons 7 and 9 is performed for detection of sequence variant mutations.  Fragment analysis of exon 7 is also performed for enhanced detection of heterozygous insertion/deletion mutations. The SNP genotype at rs16754 is reported.  Testing is performed on plasma for increased sensitivity whenever possible.    

Molecular
ZAP-70 Lymphoid Panel

Available as global and tech-only. Markers are CD3, CD5, CD19, CD45, and ZAP-70.

Flow Cytometry
ZAP70A prognostic factor in CLL/SLL. Immunohistochemistry (IHC)
ZRSR2 Mutation Analysis

Bi-directional sequencing of exons 5 and 7-11 of the ZRSR2 gene.

Molecular